Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs). It exhibits anticancer activity and is used in the treatment of small cell lung cancer (SCLC).
Reinheit:
95.00%
CAS Nummer:
[1613313-01-1]
Target-Kategorie:
Gamma-secretase
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten